The renin-angiotensin system (RAS) is a major regulatory system of cardiovascular and renal function. Many new aspects of this system have been revealed in recent years, leading to new therapeutic approaches. It’s well known that RAS blocking agents have potent antiatherosclerotic effects, which are mediated by their antihypertensive, anti-inflammatory, antiproliferative, and oxidative stress lowering properties. Inhibitors of RAS are now first-line treatments for hypertensive target organ damage. Their effects are greater than expected by their ability to lower blood pressure. Angiotensin receptor blockers reduce the frequency of atrial fibrillation and stroke, are also able to prevent cardiovascular and renal events in diabetic patients. Thus, blockade of RAS represents one of the most important strategies in order to reduce cardiovascular risk.
Angiotensin Stroke ACE-inhibitor Angiotensin II type 1 receptors blocking agent
Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BMW (2007) Renin-angiotensin system and cardiovascular risk. Lancet 369:1208–1219PubMedCrossRefGoogle Scholar
Phillips MI, Colin Sumners C (1998) Angiotensin II in central nervous system physiology. Regulatory Peptides 78:1–11PubMedCrossRefGoogle Scholar
Thone.Reineke C, Steckelings UM, Unger T (2006) Angiotensin receptor blockers and cerebral protection in stroke. J Hypertens 24:S115–S121CrossRefGoogle Scholar
Gorelick PB (2002) Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy. Stroke 33:862–875PubMedCrossRefGoogle Scholar
Farmer JA, Torre-Aimone G (2001) The renin angiotensin system as a risk factors for coronary artery disease. Curr Atheroscleros Rep 3:117–124CrossRefGoogle Scholar
Werner N, Kosiol S, Schiegl T et al (2005) Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353:999–1007PubMedCrossRefGoogle Scholar